A Review of Malignant Meningiomas: Diagnosis, Characteristics, and Treatment

Overview

Journal J Neurooncol

Publisher Springer

Date 2010 Aug 24

PMID 20730473

Citations 44

Authors

Simon Hanft

Peter Canoll

Jeffrey N Bruce

Affiliations

Soon will be listed here.

Abstract

Anaplastic or malignant meningiomas (WHO Grade III) represent the most rare but aggressive subtype, accounting for 1-3% of all intracranial meningiomas. Due in large part to their scarcity, malignant meningiomas have been understudied and therefore represent an area where significant clinical advances may be made. To this point, our understanding of the genetic and histologic attributes of these lesions has grown, though the management and treatment of these aggressive tumors is less well elucidated and thus has room for further study. In this review, we describe the current understanding of malignant meningiomas in terms of their genetic alterations and unique histologic markers. Using this as a foundation, we will then discuss the current therapeutic strategies for managing these lesions and the future direction that such interventions may take.

Citing Articles

Sellar and perisellar meningiomas: effects on pituitary function in a Spanish cohort observational study.

Guerrero-Perez F, Biagetti B, Paja-Fano M, Menendez-Torre E, Rivero G, Dios E Pituitary. 2024; 28(1):12.

PMID: 39733084 DOI: 10.1007/s11102-024-01484-y.

Malignant Neoplasm of the Meninges: A 20-Year Retrospective Study to Assess Trends and Disparities in Place of Death.

Senan A, John S, Hyderi F, Jean Y, Godavarthi A, Adhikari R Cureus. 2024; 16(9):e69424.

PMID: 39411587 PMC: 11473263. DOI: 10.7759/cureus.69424.

A nomogram to predict cancer-specific mortality in adult patients with malignant meningioma: a competing risk analysis.

Zhang H, Li J, Wan X, Liu Z Discov Oncol. 2024; 15(1):394.

PMID: 39217259 PMC: 11365918. DOI: 10.1007/s12672-024-01263-y.

Anaplastic Transformation of Sphenoid Wing Meningioma With Orbital and Cavernous Sinus Invasion: Unveiling the Aggressive Nature.

Penchev P, Kalnev B, Petrova S, Petrov P, Kalnev M Cureus. 2024; 16(3):e57025.

PMID: 38681274 PMC: 11046492. DOI: 10.7759/cureus.57025.

Radiotherapy intensification for atypical and malignant meningiomas: A systematic review.

Gaito S, Goyal L, Rieu R, France A, Burnet N, Barker C Neurooncol Pract. 2024; 11(2):115-124.

PMID: 38496911 PMC: 10940825. DOI: 10.1093/nop/npad077.

References

Jolapara M, Kesavadas C, Radhakrishnan V, Thomas B, Gupta A, Bodhey N . Role of diffusion tensor imaging in differentiating subtypes of meningiomas. J Neuroradiol. 2010; 37(5):277-83. DOI: 10.1016/j.neurad.2010.03.001. View

Shino A, Nakasu S, Matsuda M, Handa J, Morikawa S, Inubushi T . Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy. J Neurosurg. 1999; 91(6):928-34. DOI: 10.3171/jns.1999.91.6.0928. View

Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamarides M, Menei P . WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol. 2009; 95(3):367-375. DOI: 10.1007/s11060-009-9934-0. View

Norden A, Drappatz J, Wen P . Targeted drug therapy for meningiomas. Neurosurg Focus. 2007; 23(4):E12. DOI: 10.3171/FOC-07/10/E12. View

Rajaram V, Brat D, Perry A . Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical and genetic markers. Hum Pathol. 2005; 35(11):1413-8. DOI: 10.1016/j.humpath.2004.07.017. View

Pasquier D, Bijmolt S, Veninga T, Rezvoy N, Villa S, Krengli M . Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys. 2008; 71(5):1388-93. DOI: 10.1016/j.ijrobp.2007.12.020. View

Jaaskelainen J, Haltia M, Servo A . Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986; 25(3):233-42. DOI: 10.1016/0090-3019(86)90233-8. View

Chamberlain M, Glantz M, Fadul C . Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007; 69(10):969-73. DOI: 10.1212/01.wnl.0000271382.62776.b7. View

Ozen O, Demirhan B, Altinors N . Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin Neuropathol. 2005; 24(5):219-24. View

10.

Milosevic M, Frost P, Laperriere N, Wong C, Simpson W . Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys. 1996; 34(4):817-22. DOI: 10.1016/0360-3016(95)02166-3. View

11.

Commins D, Atkinson R, Burnett M . Review of meningioma histopathology. Neurosurg Focus. 2007; 23(4):E3. DOI: 10.3171/FOC-07/10/E3. View

12.

Boskos C, Feuvret L, Noel G, Habrand J, Pommier P, Alapetite C . Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys. 2009; 75(2):399-406. DOI: 10.1016/j.ijrobp.2008.10.053. View

13.

Leone P, Bello M, De Campos J, Vaquero J, Sarasa J, Pestana A . NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene. 1999; 18(13):2231-9. DOI: 10.1038/sj.onc.1202531. View

14.

Bostrom J, Wolter M, Blaschke B, Weber R, Lichter P, Ichimura K . Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol. 2001; 159(2):661-9. PMC: 1850553. DOI: 10.1016/S0002-9440(10)61737-3. View

15.

Ribalta T, McCutcheon I, Aldape K, Bruner J, Fuller G . The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol. 2004; 28(11):1532-6. DOI: 10.1097/01.pas.0000141389.06925.d5. View

16.

Toh C, Castillo M, Wong A, Wei K, Wong H, Ng S . Differentiation between classic and atypical meningiomas with use of diffusion tensor imaging. AJNR Am J Neuroradiol. 2008; 29(9):1630-5. PMC: 8118781. DOI: 10.3174/ajnr.A1170. View

17.

Hsu C, Pai C, Kao H, Hsueh C, Hsu W, Lo C . Do aggressive imaging features correlate with advanced histopathological grade in meningiomas?. J Clin Neurosci. 2010; 17(5):584-7. DOI: 10.1016/j.jocn.2009.09.018. View

18.

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

19.

Riemenschneider M, Perry A, Reifenberger G . Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006; 5(12):1045-54. DOI: 10.1016/S1474-4422(06)70625-1. View

20.

Perry A, Scheithauer B, Stafford S, Lohse C, Wollan P . "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer. 1999; 85(9):2046-56. DOI: 10.1002/(sici)1097-0142(19990501)85:9<2046::aid-cncr23>3.0.co;2-m. View